Under ERT, ADA-positive FD patients showed a tendency toward higher C3a levels (49,538 ± 7,982 ng/ml; p=0.09) (Figure 3B) but not C5a levels (45.1 ± 8.1 ng/ml) (Figure 3F) than ADA negative FD patients (C3a: 24,984 ± 10,960 ng/ml; C5a: 32.1 ± 10.5 ng/ml) (Figures 3C, G). This evidence concerns the gene C5AR1 and Fabry disease.